PMC:7784786 / 9878-10122 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"316","span":{"begin":147,"end":154},"obj":"Species"},{"id":"352","span":{"begin":167,"end":189},"obj":"Disease"},{"id":"353","span":{"begin":194,"end":199},"obj":"Disease"}],"attributes":[{"id":"A316","pred":"tao:has_database_id","subj":"316","obj":"Tax:9606"},{"id":"A352","pred":"tao:has_database_id","subj":"352","obj":"MESH:D009202"},{"id":"A353","pred":"tao:has_database_id","subj":"353","obj":"MESH:D012769"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ignificant reduction is detecting at day 7 (pretreatment: 156 U/l, D7: 40 U/l) as is showed in Figure 2B. After 10 days of admission into the ICU, patient presented a myocardial dysfunction and shock that required vasoactive support with norepi"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T41","span":{"begin":194,"end":199},"obj":"Phenotype"}],"attributes":[{"id":"A41","pred":"hp_id","subj":"T41","obj":"http://purl.obolibrary.org/obo/HP_0031273"}],"text":"ignificant reduction is detecting at day 7 (pretreatment: 156 U/l, D7: 40 U/l) as is showed in Figure 2B. After 10 days of admission into the ICU, patient presented a myocardial dysfunction and shock that required vasoactive support with norepi"}

{"project":"LitCovid-sentences","denotations":[{"id":"T88","span":{"begin":58,"end":70},"obj":"Sentence"},{"id":"T89","span":{"begin":71,"end":105},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"ignificant reduction is detecting at day 7 (pretreatment: 156 U/l, D7: 40 U/l) as is showed in Figure 2B. After 10 days of admission into the ICU, patient presented a myocardial dysfunction and shock that required vasoactive support with norepi"}